A Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male Patients

Inclusion Criteria: * In good general health as determined by no clinically significant findings on medical history, physical examination, vital signs, 12-lead electrocardiogram, and clinical laboratory measurements * Body mass index within 18 kg/m2 to 32 kg/m2, inclusive * Non-tobacco users * Clinical laboratory values within protocol-defined parameters * Negative hepatitis panel (including hepatitis B surface antigen \[HBsAg\] and hepatitis C virus antibody \[anti-HCV\]),and negative human immunodeficiency virus (HIV) antibody screens * Negative test for selected drugs of abuse * Agrees to protocol-defined use of effective contraception Exclusion Criteria: * Significant history or manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological or psychiatric disorder, as determined by the Principal Investigator * History or presence of an abnormal electrocardiogram * History of stomach or intestinal surgery resection that would potentially alter absorption and/or excretion of orally administered drugs * Screening serum total testosterone of \<200 ng/dL * History of hypersensitivity reaction to the study drug, related compounds or excipients used in the formulation * Receipt of an investigational drug within 5 half-lives or 30 days prior to Day -1, whichever is longer * Abnormal diet during the 30 days prior to Day 1 * Donation of blood or significant loss of blood within 56 days or plasma within 14 days prior to Day -1 * Planned donation of blood or plasma from Screening through Study Completion, Day 21 * Receipt of blood products within 2 months prior to Day 1 * History of protocol-defined alcohol abuse * Known or suspected use of illicit drugs within the last year * Use of any medication on a chronic basis * Use of any prescription medications/products or over-the-counter non-prescription preparations within 5 half-lives or 7 days prior to Day -1 unless deemed acceptable by the Sponsor * Consumption of alcohol-containing foods or beverages within 24 hours prior to the first Check-in (Day -1) * Unwillingness to abstain from alcohol consumption from Day -1 to Study Completion (Day21) * Consumption of caffeine-containing or grapefruit-containing foods or beverages within 72 hours prior to Day -1 * Unwillingness to abstain from caffeine-containing or grapefruit-containing foods or beverages from Day -1 through Study Completion (Day21) * Presence of sexual dysfunction or any medical condition that would affect sexual function * Unwillingness to refrain from strenuous exercise from 48 hours prior to Day -1 and for the duration of the study * Presence of any condition that, in the opinion of the Investigator, would limit the participant's ability to complete and/or participate in this study * Unwillingness to refrain from using any tobacco or nicotine-containing products during screening and throughout the study to Study Completion (Day 21)